Change in SV and spleen length from baseline in patients with MF. Percentage change from baseline in SV at (A) 12 weeks and (B) 24 weeks; and (C) change in spleen length by study visit up to 24 weeks in patients treated with add-on parsaclisib plus ruxolitinib. Blue bars and line represent daily-to-weekly parsaclisib dosing, and red bars and line represent all-daily parsaclisib dosing. Evaluable patients were those receiving ≥1 dose of study drug and had SV baseline assessment with a nonzero value. Dotted lines represent 25% and 35% decrease in SV from baseline. ∗Patient had best percentage change from baseline >100%. ^†The number of patients in each dosing group who had palpable spleen length evaluated at the follow-up time point. SD, standard deviation.